Petros Christopoulos

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (5)

Nikos Vlahos

Professor and chairman

National and Kapodistrian University of Athens

Claudia Lengerke

University Hospital Tübingen

Marcel Wiesweg

University Hospital Essen

Paul Hofman

Université Côte d'Azur

Matthias Scheffler

University Hospital Bonn

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Petros Christopoulos

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (5)

Nikos Vlahos

Claudia Lengerke

Marcel Wiesweg

Paul Hofman

Matthias Scheffler

Make your next move.

Petros Christopoulos

Research Interests

Explore related searches

Contact this professor

Articles (20)

Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer

Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome

Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation

Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany

Fractionated stereotactic radiotherapy of brainstem metastases – Clinical outcome and prognostic factors

MOMENT registry: Patients with advanced non-small-cell lung cancer harboring &lt;i&gt;MET&lt;/i&gt; exon 14 skipping treated with systemic therapy.

Abstracts of the 16th European Congress of Paediatric and Adolescent Gynaecology

A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers.

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.

Impact of different parametric Patlak imaging approaches and comparison with a 2-tissue compartment pharmacokinetic model with a long axial field-of-view (LAFOV) PET/CT in oncological patients.

Real‐world data for precision cancer medicine—A European perspective

Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations

Dynamic contrast enhanced MRI of pulmonary adenocarcinomas for early risk stratification: higher contrast uptake associated with response and better prognosis.

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors.

Double trouble: combined large-cell neuroendocrine and small-cell lung carcinoma.

Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial.

Real-world efficacy and safety of mobocertinib in <i>EGFR</i> exon 20 insertion-mutated lung cancer.

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.

Collaborators (5)

Nikos Vlahos

Claudia Lengerke

Marcel Wiesweg

Paul Hofman

Matthias Scheffler

Make your next move.

MOMENT registry: Patients with advanced non-small-cell lung cancer harboring <i>MET</i> exon 14 skipping treated with systemic therapy.